Cargando…
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410855/ https://www.ncbi.nlm.nih.gov/pubmed/32253677 http://dx.doi.org/10.1245/s10434-020-08418-5 |
_version_ | 1783568266310975488 |
---|---|
author | Wei, Xiaoting Wu, Di Li, Hang Zhang, Rui Chen, Yu Yao, Hong Chi, Zhihong Sheng, Xinan Cui, Chuanliang Bai, Xue Qi, Zhonghui Li, Ke Lan, Shijie Chen, Lizhu Guo, Rui Yao, Xinyu Mao, Lili Lian, Bin Kong, Yan Dai, Jie Tang, Bixia Yan, Xieqiao Wang, Xuan Li, Siming Zhou, Li Balch, Charles M. Si, Lu Guo, Jun |
author_facet | Wei, Xiaoting Wu, Di Li, Hang Zhang, Rui Chen, Yu Yao, Hong Chi, Zhihong Sheng, Xinan Cui, Chuanliang Bai, Xue Qi, Zhonghui Li, Ke Lan, Shijie Chen, Lizhu Guo, Rui Yao, Xinyu Mao, Lili Lian, Bin Kong, Yan Dai, Jie Tang, Bixia Yan, Xieqiao Wang, Xuan Li, Siming Zhou, Li Balch, Charles M. Si, Lu Guo, Jun |
author_sort | Wei, Xiaoting |
collection | PubMed |
description | BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large tertiary hospitals in China were extracted. Chi square tests were used to compare basic characteristics between primary sites of sole, palm and nail bed. Melanoma-specific survival (MSS) differences based on primary sites were compared by log-rank tests and multivariate Cox regressions were used to identify prognostic factors for MSS. RESULTS: In total, 1157 AM patients were included. The sole group had a more advanced initial stage, deeper Breslow thickness, higher recurrence rate and distant metastases risk (all P < 0.05). The proportion of age < 65 years and ulceration were statistically lower in nail bed and palm groups, respectively. A total of 294 patients underwent sentinel lymph node biopsy and rates of positive SLN status had no statistical difference across primary sites. Among 701 patients with genetic profiles, the mutational frequency of BRAF, C-KIT, and PDGFRA were similar except for NRAS (higher in sole group, P = 0.0102). The median MSS of sole, nail bed and palm patients were 65.0 months, 112.0 months, and not reached, respectively (log-rank P = 0.0053). In multivariate analyses, primary site, initial stage, ulceration and recurrence were the prognostic factors for MSS in overall population, but the statistical significance varied over primary sites. CONCLUSIONS: Substantial clinicopathological and survival heterogeneities exist across different primary sites in the AM population. Sole melanoma has worse prognosis compared with palm and nail bed subtypes. |
format | Online Article Text |
id | pubmed-7410855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74108552020-08-17 The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma Wei, Xiaoting Wu, Di Li, Hang Zhang, Rui Chen, Yu Yao, Hong Chi, Zhihong Sheng, Xinan Cui, Chuanliang Bai, Xue Qi, Zhonghui Li, Ke Lan, Shijie Chen, Lizhu Guo, Rui Yao, Xinyu Mao, Lili Lian, Bin Kong, Yan Dai, Jie Tang, Bixia Yan, Xieqiao Wang, Xuan Li, Siming Zhou, Li Balch, Charles M. Si, Lu Guo, Jun Ann Surg Oncol Melanoma BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large tertiary hospitals in China were extracted. Chi square tests were used to compare basic characteristics between primary sites of sole, palm and nail bed. Melanoma-specific survival (MSS) differences based on primary sites were compared by log-rank tests and multivariate Cox regressions were used to identify prognostic factors for MSS. RESULTS: In total, 1157 AM patients were included. The sole group had a more advanced initial stage, deeper Breslow thickness, higher recurrence rate and distant metastases risk (all P < 0.05). The proportion of age < 65 years and ulceration were statistically lower in nail bed and palm groups, respectively. A total of 294 patients underwent sentinel lymph node biopsy and rates of positive SLN status had no statistical difference across primary sites. Among 701 patients with genetic profiles, the mutational frequency of BRAF, C-KIT, and PDGFRA were similar except for NRAS (higher in sole group, P = 0.0102). The median MSS of sole, nail bed and palm patients were 65.0 months, 112.0 months, and not reached, respectively (log-rank P = 0.0053). In multivariate analyses, primary site, initial stage, ulceration and recurrence were the prognostic factors for MSS in overall population, but the statistical significance varied over primary sites. CONCLUSIONS: Substantial clinicopathological and survival heterogeneities exist across different primary sites in the AM population. Sole melanoma has worse prognosis compared with palm and nail bed subtypes. Springer International Publishing 2020-04-06 2020 /pmc/articles/PMC7410855/ /pubmed/32253677 http://dx.doi.org/10.1245/s10434-020-08418-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Melanoma Wei, Xiaoting Wu, Di Li, Hang Zhang, Rui Chen, Yu Yao, Hong Chi, Zhihong Sheng, Xinan Cui, Chuanliang Bai, Xue Qi, Zhonghui Li, Ke Lan, Shijie Chen, Lizhu Guo, Rui Yao, Xinyu Mao, Lili Lian, Bin Kong, Yan Dai, Jie Tang, Bixia Yan, Xieqiao Wang, Xuan Li, Siming Zhou, Li Balch, Charles M. Si, Lu Guo, Jun The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title | The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title_full | The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title_fullStr | The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title_full_unstemmed | The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title_short | The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma |
title_sort | clinicopathological and survival profiles comparison across primary sites in acral melanoma |
topic | Melanoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410855/ https://www.ncbi.nlm.nih.gov/pubmed/32253677 http://dx.doi.org/10.1245/s10434-020-08418-5 |
work_keys_str_mv | AT weixiaoting theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT wudi theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lihang theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT zhangrui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chenyu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yaohong theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chizhihong theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT shengxinan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT cuichuanliang theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT baixue theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT qizhonghui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT like theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lanshijie theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chenlizhu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT guorui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yaoxinyu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT maolili theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lianbin theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT kongyan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT daijie theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT tangbixia theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yanxieqiao theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT wangxuan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lisiming theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT zhouli theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT balchcharlesm theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT silu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT guojun theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT weixiaoting clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT wudi clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lihang clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT zhangrui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chenyu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yaohong clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chizhihong clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT shengxinan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT cuichuanliang clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT baixue clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT qizhonghui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT like clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lanshijie clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT chenlizhu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT guorui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yaoxinyu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT maolili clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lianbin clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT kongyan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT daijie clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT tangbixia clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT yanxieqiao clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT wangxuan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT lisiming clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT zhouli clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT balchcharlesm clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT silu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma AT guojun clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma |